Pink SheetMFN Drug Pricing Unlikely To Be A Widespread Near-Term Threat BIO attempted to offer some insight into the Trump Administration’s plan to institute most favored nation (MFN) drug pricing, which requir
ScripEli Lilly and Verve Therapeutics agreed to a buyout on June 17 valued at approximately $1bn with a contingent value right (CVR) that could be attainable, bringing the total deal value to around $1.3bn
ScripAstraZeneca has unveiled a major new alliance with up-and-coming China’s CSPC Pharmaceuticals to discover and develop novel oral drug candidates, a collaboration which underscores the emergence of the
ScripUCB has become the latest Europe drugmaker to pledge major manufacturing investments in the US amid the pressure being put on the pharmaceutical sector by President Trump administration to move more d